SUMMARY OF PRODUCT CHARACTERISTICS

1. NAME of the veterinary medicinal product

Iso-Vet 1000 mg/g Inhalation Vapour, liquid (All CMS except Spain,

Portugal, Sweden, Denmark, Finland & Iceland)

IsoVet 1000 mg/g Inhalation Vapour, liquid (Spain & Portugal)

Attane vet 1000 mg/g Inhalation Vapour, liquid (Denmark, Sweden, Finland & Iceland)

2. QUALITATIVE AND QUANTITATIVE COMPOSITION

Per gram:

Active Substance:

Isoflurane 1000 mg

The veterinary medicinal product contains no excipients.

3. PHARMACEUTICAL FORM

Inhalation vapour, Liquid.

Clear, colourless, mobile, heavy liquid

4. Clinical Particulars

4.1 Target Species

Horses, dogs, cats, ornamental birds, reptiles, rats, mice, hamsters, chinchillas, gerbils, guinea pigs and ferrets.

4.2 Indications for use, specifying the target species

Induction and maintenance of general anaesthesia.

4.3 Contra-indications

This product should not be used in animals with a known sensitivity to isoflurane other halogenated inhalation anesthetics or a known susceptibility to malignant hyperthermia.

4.4 Special warnings for each target species

The ease and rapidity of alteration of the depth of anaesthesia with Isoflurane and its low metabolism, may be considered advantageous for its use in special groups of patients such as the old or young, and those with impaired hepatic, renal or cardiac function.

4.5 Special precautions for use

i) Special precautions for use in animals

Isoflurane has little or no analgesic properties. Adequate analgesia should always be given before surgery. The analgesic requirements of the patient should be considered before general anaesthesia is ended.

The use of the product in patients with cardiac disease should be considered only after a risk/ benefit assessment by the veterinarian.

It is important to monitor breathing and pulse for the frequency and its features. Respiratory arrest should be treated by assisted ventilation. It is important to maintain airways free and properly oxygenate tissues during the maintenance of anaesthesia. In the case of cardiac arrest, perform a complete cardio pulmonary resuscitation.

The metabolism in small mammals, can be affected by decreases in body temperature, due to high surface area to body weight ratio. Therefore body temperature should be monitored and kept stable.

Reptiles may be difficult to induce with inhalation agents due to breath holding.

Like other inhalation anaesthetics of this type, isoflurane depresses the respiratory and cardiovascular systems.

ii) Special precautions to be taken by the person administering the medicinal product to animals

• Do not breathe the vapour. Users should consult their National Authority for advice on Occupational Exposure Standards for isoflurane.

• Operating rooms and recovery areas should be provided with adequate ventilation or scavenging systems to prevent the accumulation of anaesthetic vapour.

• All scavenging/ extraction systems must be adequately maintained.

• Pregnant and/or breast- feeding women should avoid exposure to the product and should avoid operating rooms and recovery areas.

• Avoid using masking procedures for prolonged induction and maintenance of general anaesthesia. Use cuffed endotracheal intubation when possible for the administration of isoflurane during maintenance of general anaesthesia.

• To protect the environment, it is considered good practice to use charcoal filters with scavenging equipment.

• Care should be taken when dispensing isoflurane, with any spillage removed immediately using an inert and absorbent material e.g. sawdust.

• Wash any splashes from skin and eyes, and avoid contact with the mouth.

• If severe accidental exposure occurs remove the operator from the source of exposure, seek urgent medical assistance and show this label.

• Halogenated anaesthetic agents may induce liver damage. In case of isoflurane this is an idiosyncratic response very rarely seen after repeated exposure.

• Advice to Doctors: Ensure a patent airway and give symptomatic and supportive treatment. Note that adrenaline and catecholamines may cause cardiac dysrhythmias.

iii) Other Precautions:

Although anaesthetics have a low potential for damage to the atmosphere, it is good practice to use charcoal filters with scavenging equipment, rather than to discharge them into the air.

4.6 Adverse reactions (frequency and seriousness)

Isoflurane produces hypotension and respiratory depression in a dose- related manner.

Adverse reaction	Frequency
Cardiac arrhythmias	Rare	More than 1 but less than 10 animals in 10000 animals
Transient bradycardia	Rare	More than 1 but less than 10 animals in 10000 animals
Malignant hyperthermia	Very rare	Less than 1 animal in 10000 animals, including isolated reports

.

Although Isoflurane can be used during cranial surgery and in patients with head injuries, increased cerebral blood flow and intracranial pressure can occur. Hyperventilating the patient can reduce the increased intracranial pressure.

4.7 Use during pregnancy and lactation or lay

Although Isoflurane has been used safely during caesarean section in the dog and cat, no full data are available on its use during pregnancy and lactation in the target species. Use in pregnant and lactating animals should, therefore only be considered following a risk/benefit assessment by the veterinary surgeon.

4.8 Interaction with other medicaments and other forms of interaction

The action of muscle relaxants in man, especially those of the nondepolarising (competitive) type such as atracurium, pancuronium or vecuronium, is enhanced by isoflurane. Similar potentiation might be expected to occur in the target species, although there is little direct evidence to this effect. Concurrent inhalation of nitrous oxide enhances the effect of isoflurane in man and similar potentiation might be expected in animals.

The concurrent use of sedative or analgesic drugs is likely to reduce the level of isoflurane required to produce and maintain anaesthesia.

Some examples are given in 4.9.

Isoflurane has a weaker sensitising action on the myocardium, to the effects of circulating dysrhythmogenic catecholamines, than halothane

Delivery in nitrous oxide and premedication with agents such as acepromazine, opioids, benzodiazepines and alpha-2-adrenoreceptor agonists are compatible with isoflurane use; however, the concurrent use of sedative or analgesic drugs is likely to reduce the level of isoflrane required to produce and maintain anaesthesia. Some examples are given in 4.9.

Isoflurane may be degraded to carbon monoxide by dried carbon dioxide absorbents.

4.9 Amount(s) to be administered and administration route

Isoflurane should be administered using an accurately calibrated vaporiser in an appropriate anaesthetic circuit, since levels of anaesthesia may be altered rapidly and easily.

Isoflurane may be administered in oxygen or oxygen/nitrous oxide

mixtures.

The MAC (minimal alveolar concentration in oxygen) or effective dose ED₅₀values and suggested concentrations given below for the target species should be used as a guide or starting point only. The actual concentrations required in practice will depend on many variables, including the concomitant use of other drugs during the anaesthetic procedure and the clinical status of the patient.

Isoflurane may be used in conjunction with other drugs commonly used in veterinary anaesthetic regimes for premedication, induction and analgesia. Some specific examples are given in the individual species information. The use of analgesia for painful procedures is consistent with good veterinary practice.

Recovery from Isoflurane anaesthesia is usually smooth and rapid. The analgesic requirements of the patient should be considered before the termination of general anaesthesia.

The lowest effective dose should be administered, and, as with all anaesthetics, the correct dose is the minimum that achieves the desired level of anaesthesia.

HORSE

The MAC for isoflurane in the horse is approximately 1.31%

Premedication

Isoflurane may be used with other drugs commonly used in veterinary anaesthetic regimes. The following drugs have been found to be compatible with isoflurane: acepromazine, alfentanil, atracurium, butorphanol, detomidine, diazepam, dobutamine, dopamine, guaiphenesin, ketamine, morphine, pentazocine, pethidine, thiamylal, thiopentone and xylazine. Drugs used for premedication should be selected for the individual patient. However, the potential interactions below should be noted.

Interactions:

Detomidine and xylazine have been reported to reduce the MAC for Isoflurane in horses.

Induction

As it is not normally practicable to induce anaesthesia in adult horses using isoflurane, induction should be by the use of a short acting barbiturate such as thiopentone sodium, ketamine or guaiphenesin. Concentrations of 3 to 5% isoflurane may then be used to achieve the desired depth of anaesthesia in 5 to 10 minutes

Isoflurane at a concentration of 3 to 5% in a high flow oxygen may be used for induction in foals.

Maintenance

Anaesthesia may be maintained using 1.5% to 2.5% isoflurane.

Recovery

Recovery is usually smooth and rapid.

DOG

The MAC for isoflurane in the dog is approximately 1.28%.

Premedication

Isoflurane may be used with other drugs commonly used in veterinary anaesthetic regimes. The following drugs have been found to be compatible with isoflurane: acepromazine, atropine, butorphanol, buprenorphine, bupivacaine, diazepam, dobutamine, ephedrine, epinephrine, etomidate, glycopyrrolate, ketamine, medetomidine, midazolam, methoxamine, oxymorphone, propofol, thiamylal, thiopentone and xylazine. Drugs used for premedication should be selected for the individual patient. However, the potential interactions below should be noted.

Interactions:

Morphine, oxymorphone, acepromazine, medetomidine, medetomidine plus midazolam have been reported to reduce the MAC for isoflurane in dogs.

The concomitant administration of midazolam/ketamine during isoflurane anaesthesia may result in marked cardiovascular effects, particularly arterial hypotension.

The depressant effects of propanolol on myocardial contractility are reduced during isoflurane anaesthesia, indicating a moderate degree of β-receptor activity.

Induction

Induction is possible by face mask using up to 5% isoflurane, with or without premedication.

Maintenance

Anaesthesia may be maintained using 1.5% to 2.5% isoflurane.

Recovery

Recovery is usually smooth and rapid.

CAT

The MAC for isoflurane in the cat is approximately 1.63%.

Premedication

Isoflurane may be used with other drugs commonly used in veterinary anaesthetic regimes. The following drugs have been found to be compatible with isoflurane: acepromazine, atracurium, atropine, diazepam, ketamine, and oxymorphone. Drugs used for premedication should be selected for the individual patient. However, the potential interactions below should be noted.

Interactions:

Intravenous administration of midazolam- butorphanol has been reported to alter several cardio-respiratory parameters in isoflurane- induced cats as has epidural fentanyl and medetomidine. Isoflurane has been shown to reduce the sensitivity of the heart to adrenaline (epinephrine).

Induction

Induction is possible by face mask using up to 4% isoflurane, with or without premedication.

Maintenance

Anaesthesia may be maintained using 1.5% to 3% isoflurane.

Recovery

Recovery is usually smooth and rapid.

ORNAMENTAL BIRDS

Few MAC/ED₅₀values have been recorded. Examples are 1.34% for the Sandhill crane, 1.45% for the racing pigeon, reduced to 0.89% by the administration of midazolam, and 1.44% for cockatoos, reduced to 1.08% by the administration of butorphanol analgesic.

The use of isoflurane anaesthesia has been reported for many species, from small birds such as zebra finches, to large birds such as vultures, eagles and swans.

Drug interactions/compatibilities

Propofol has been demonstrated in the literature to be compatible with isoflurane anaesthesia in swans.

Interactions:

Butorphanol has been reported to reduce the MAC for isoflurane in cockatoos. Midazolam has been reported to reduce the MAC for isoflurane in pigeons.

Induction

Induction with 3 to 5% isoflurane is normally rapid. Induction of anaesthesia with propofol, followed by isoflurane maintenance, has been reported for swans.

Maintenance

The maintenance dose depends on the species and individual. Generally, 2 to 3% is suitable and safe.

Only 0.6 to 1% may be needed for some stork and heron species.

Up to 4 to 5% may be needed for some vultures and eagles.

3.5 to 4% may be needed for some ducks and geese.

Generally, birds respond very rapidly to changes in concentration of

isoflurane.

Recovery

Recovery is usually smooth and rapid.

REPTILES

Isoflurane is considered by several authors to be the anaesthetic of choice for many species. The literature records its use on a wide variety of reptiles (eg. various species of lizard, tortoise, iguanas, chameleon and snakes).

The ED₅₀was determined in the desert iguana to be 3.14% at 35˚C and 2.83% at 20˚C.

Drug interactions/ compatibilities

No specific publications on reptiles have reviewed compatibilities or interactions of other drugs with isoflurane anaesthesia.

Induction

Induction is usually rapid at 2 to 4% isoflurane.

Maintenance

1 to 3% is a useful concentration

Recovery

Recovery is usually smooth and rapid

RATS, MICE, HAMSTERS, CHINCHILLAS, GERBILS, GUINEA PIGS AND FERRETS

Isoflurane has been recommended for anaesthesia of a wide variety of ‘small mammals’ (eg. rats, mouse, hamster, chinchilla, gerbil, guinea pig and ferret).

The MAC for mice has been cited as 1.34%, and for the rat as 1.38%, 1.46% and 2.4%.

Drug interactions/ compatibilities

No specific publications on small mammals have reviewed compatibilities or interactions of other drugs with isoflurane anaesthesia.

Induction

Isoflurane concentration 2 to 3%.

Maintenance

Isoflurane concentration 0.25 to 2%.

Recovery

Recovery is usually smooth and rapid.

Species	MAC (%)	Induction (%)	Maintenance (%)	Recovery
Horse	1.31	3.0 – 5.0 (foals)	1.5 – 2.5	Smooth and rapid
Dog	1.28	Up to 5.0	1.5 – 2.5	Smooth and rapid
Cat	1.63	Up to 4.0	1.5 – 3.0	Smooth and rapid
Ornamental birds	See posology	3.0 – 5.0	See posology	Smooth and rapid
Reptiles	See posology	2.0 – 4.0	1.0 – 3.0	Smooth and rapid
Rats, mice, hamsters, chinchillas, gerbils, guinea pigs and ferrets	1.34 (mouse) 1.38/1.46/2.40 (rat)	2.0 – 3.0	0.25 – 2.0	Smooth and rapid

4.10 Overdose (symptoms, emergency procedures, antidotes) if necessary

Isoflurane overdose may result in profound respiratory depression. Therefore, respiration must be monitored closely and supported when necessary with supplementary oxygen and/ or assisted ventilation.

In cases of severe cardiopulmonary depression, administration of isoflurane should be discontinued, the breathing circuit should be flushed with oxygen, the existence of a patent airway ensured, and assisted or controlled ventilation with pure oxygen initiated. Cardiovascular depression should be treated with plasma expanders, pressor agents, antiarrhythmic agents or other appropriate techniques.

In the case of cardiac arrest, perform a complete cardio pulmonary resuscitation.

4.11 Withdrawal period(s)

Horses: meat and offal 2 days

Do not use in mares producing milk for human consumption.

5. PHARMACOLOGICAL PROPERTIES

Pharmacotherapeutic group: Anaesthetic, general - halogenated hydrocarbons

ATCvetcode: QN01AB06

5.1 Pharmacodynamic properties

Isoflurane is a general inhalation anaesthetic of the halogenated hydrocarbon type. It is a volatile liquid, allowing rapid changes in the depth of anaesthesia by a suitably skilled anaesthetist. Isoflurane produces unconsciousness by its action on the central nervous system. It has little or no analgesic properties.

The absorption and distribution of isoflurane is rapid, resulting in relatively rapid induction of anaesthesia and smooth recovery.

Like other inhalation anaesthetics of this type, isoflurane depresses the respiratory and cardiovascular systems.

Isoflurane may sensitise the myocardium to circulating dysrhythmogenic catecholamines. Isoflurane generally produces good muscle relaxation, but the degree of post-operative analgesia is slight because of the rapid recovery.

Isoflurane has little or no analgesic property.

5.2 Pharmacokinetic Particulars

Isoflurane is absorbed on inhalation and is rapidly distributed via the bloodstream to other tissues, including the brain. Its blood/gas partition coefficient at 37ْC is 1.4. The absorption and distribution of Isoflurane and the elimination of non-metabolised isoflurane by the lungs are all rapid, with the clinical consequences of rapid induction and recovery and easy and rapid control of the depth of anaesthesia.

Metabolism of isoflurane is minimal (about 0.2%, mainly to inorganic fluoride) and almost all of the administered isoflurane is excreted unchanged by the lungs.

6. PHARMACEUTICAL PARTICULARS

6.1 List of excipients

None

6.2 Incompatibilities

Isoflurane has been reported to interact with dry carbon dioxide absorbents to form carbon monoxide. In order to minimise the risk of formation of carbon monoxide in rebreathing circuits and the possibility of elevated carboxyhaemoglobin levels, carbon dioxide absorbents should not be allowed to dry out.

6.3 Shelf-Life

Shelf-life of the veterinary medicinal product as packaged for sale: 5 years

6.4 Special precautions for storage

Do not store above 25°C. Protect from direct sunlight & direct heat.

Store in tightly closed original container.

6.5 Nature and composition of immediate packaging

Type III amber glass bottles containing 100 ml or 250 ml of Isoflurane, fitted with a black phenolic/urea screw cap with a low-density polyethylene cone insert.

Not all pack sizes may be marketed.

6.6 Special precautions for the disposal of unused veterinary medicinal product or waste materials derived from the use of such products, if appropriate

Any unused veterinary medicinal product or waste material derived from such veterinary medicinal products should be disposed of in accordance with local requirements.

7. Marketing Authorisation Holder

Piramal Healthcare UK Limited

Whalton Road,

Morpeth,

Northumberland NE61 3YA,

United Kingdom

Tel: 0044 1670562400

Fax: 0044 1670562543

8. Marketing Authorisation Number

Vm29595/4001

9. Date of first Authorisation

Date: 12^th August 2009

10. Date of revision of the text

Date: August 2014

Condition of supply: Prescription Only Medicine

Approved: 08/08/2014